Literature DB >> 16719058

Behavioral and histological characterization of intrahippocampal grafts of human bone marrow-derived multipotent progenitor cells in neonatal rats with hypoxic-ischemic injury.

Takao Yasuhara1, Noriyuki Matsukawa, Guolong Yu, Lin Xu, Robert W Mays, Jim Kovach, Robert J Deans, David C Hess, James E Carroll, Cesar V Borlongan.   

Abstract

Children born with hypoxic-ischemic (HI) brain injury account for a significant number of live births wherein no clinical treatment is available. Limited clinical trials of stem cell therapy have been initiated in a number-of neurological disorders, but the preclinical evidence of a cell-based therapy for neonatal HI injury remains in its infancy. One major postulated mechanism underlying therapeutic benefits of stem cell therapy involves stimulation of endogenous neurogenesis via transplantation of exogenous stem cells. To this end, transplantation has targeted neurogenic sites, such as the hippocampus, for brain protection and repair. The hippocampus has been shown to secrete growth factors, especially during the postnatal period, suggesting that this brain region presents as highly conducive microenvironment for cell survival. Based on its neurogenic and neurotrophic factor-secreting features, the hippocampus stands as an appealing target for stem cell therapy. Here, we investigated the efficacy of intrahippocampal transplantation of multipotent progenitor cells (MPCs), which are pluripotent progenitor cells with the ability to differentiate into a neuronal lineage. Seven-day-old Sprague-Dawley rats were initially subjected to unilateral HI injury, which involved permanent ligation of the right common carotid artery and subsequent exposure to hypoxic environment. At day 7 after HI injury, animals received stereotaxic hippocampal injections of vehicle or cryopre-served MPCs (thawed just prior to transplantation) derived either from Sprague-Dawley rats (syngeneic) or Fisher rats (allogeneic). All animals were treated with daily immunosuppression throughout the survival period. Behavioral tests were conducted on posttransplantation days 7 and 14 using the elevated body swing test and the rotarod to reveal general and coordinated motor functions. MPC transplanted animals exhibited reduced motor asymmetry and longer time spent on the rotarod than those that received the vehicle infusion. Both syngeneic and allogeneic MPC transplanted injured animals did not significantly differ in their behavioral improvements at both test periods. Immunohistochemical evaluations of graft survival after behavioral testing at day 14 posttransplantation revealed that syngeneic and allogeneic transplanted MPCs survived in the hippocampal region. These results demonstrate for the first time that transplantation of MPCs ameliorated motor deficits associated with HI injury. In view of comparable behavioral recovery produced by syngeneic and allogeneic MPC grafts, allogeneic transplantation poses as a feasible and efficacious cell replacement strategy with direct clinical application. An equally major finding is the observation lending support to the hippocampus as an excellent target brain region for stem cell therapy in treating HI injury.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16719058     DOI: 10.3727/000000006783982034

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  32 in total

Review 1.  Cell-based therapy in ischemic stroke.

Authors:  David C Hess; Cesar V Borlongan
Journal:  Expert Rev Neurother       Date:  2008-08       Impact factor: 4.618

Review 2.  Stem cell therapy for neurological disorders: A focus on aging.

Authors:  Hung Nguyen; Sydney Zarriello; Alexandreya Coats; Cannon Nelson; Chase Kingsbury; Anna Gorsky; Mira Rajani; Elliot G Neal; Cesar V Borlongan
Journal:  Neurobiol Dis       Date:  2018-09-13       Impact factor: 5.996

3.  Therapeutic potential of genetically modified mesenchymal stem cells after neonatal hypoxic-ischemic brain damage.

Authors:  Cindy Tj van Velthoven; Luca Braccioli; Hanneke Ldm Willemen; Annemieke Kavelaars; Cobi J Heijnen
Journal:  Mol Ther       Date:  2013-10-31       Impact factor: 11.454

4.  Cell Therapy From Bench to Bedside Translation in CNS Neurorestoratology Era.

Authors:  Hongyun Huang; Lin Chen; Paul Sanberg
Journal:  Cell Med       Date:  2010-01-01

Review 5.  Neuroprotection Strategies in Preterm Encephalopathy.

Authors:  Pratik Parikh; Sandra E Juul
Journal:  Semin Pediatr Neurol       Date:  2019-08-09       Impact factor: 1.636

Review 6.  Baby STEPS: a giant leap for cell therapy in neonatal brain injury.

Authors:  Cesar V Borlongan; Michael D Weiss
Journal:  Pediatr Res       Date:  2011-07       Impact factor: 3.756

Review 7.  Progress in neuroprotective strategies for preventing epilepsy.

Authors:  Munjal M Acharya; Bharathi Hattiangady; Ashok K Shetty
Journal:  Prog Neurobiol       Date:  2007-12-08       Impact factor: 11.685

8.  Pharmacological neuroprotection after perinatal hypoxic-ischemic brain injury.

Authors:  Xiyong Fan; Annemieke Kavelaars; Cobi J Heijnen; Floris Groenendaal; Frank van Bel
Journal:  Curr Neuropharmacol       Date:  2010-12       Impact factor: 7.363

9.  Intravenous grafts recapitulate the neurorestoration afforded by intracerebrally delivered multipotent adult progenitor cells in neonatal hypoxic-ischemic rats.

Authors:  Takao Yasuhara; Koichi Hara; Mina Maki; Robert W Mays; Robert J Deans; David C Hess; James E Carroll; Cesar V Borlongan
Journal:  J Cereb Blood Flow Metab       Date:  2008-07-02       Impact factor: 6.200

10.  Strategies for promoting anti-seizure effects of hippocampal fetal cells grafted into the hippocampus of rats exhibiting chronic temporal lobe epilepsy.

Authors:  Muddanna S Rao; Bharathi Hattiangady; Kiranmai S Rai; Ashok K Shetty
Journal:  Neurobiol Dis       Date:  2007-05-23       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.